Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
447 participants
INTERVENTIONAL
2005-10-31
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Etanercept liquid
50 mg Etanercept
50 mg Etanercept liquid injected SC once weekly using prefilled syringes
Enbrel liquid
50 mg Etanercept liquid injected SC once weekly using prefilled syringes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
50 mg Etanercept
50 mg Etanercept liquid injected SC once weekly using prefilled syringes
Enbrel liquid
50 mg Etanercept liquid injected SC once weekly using prefilled syringes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be able to self-inject or have someone who can do so for them
* Should have Rheumatoid Arthritis per ARA criteria and screening lab results per predefined value
Exclusion Criteria
* Any prior cyclophosphamide therapy
* Not using adequate contraception
* Pregnant or breast-feeding or any significant concurrent medical condition
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Immunex Corporation
INDUSTRY
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amgen Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kavanaugh A, Lee SJ, Weng HH, Chon Y, Huang XY, Lin SL. Patient-derived joint counts are a potential alternative for determining Disease Activity Score. J Rheumatol. 2010 May;37(5):1035-41. doi: 10.3899/jrheum.090704. Epub 2010 Feb 15.
Related Links
Access external resources that provide additional context or updates about the study.
Notice regarding posted summaries of trial results
To access clinical trial results information click on this link
FDA-approved Drug Labeling
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20050145
Identifier Type: -
Identifier Source: org_study_id